Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia

被引:134
|
作者
Selleri, C
Sato, T
DelVecchio, L
Luciano, L
Barrett, AJ
Rotoli, B
Young, NS
Maciejewski, JP
机构
[1] UNIV NAPLES FEDERICO II, SCH MED, DIV HEMATOL, NAPLES, ITALY
[2] CARDARELLI HOSP, SERV IMMUNOHEMATOL, NAPLES, ITALY
[3] NHLBI, HEMATOL BRANCH, BETHESDA, MD 20892 USA
关键词
D O I
10.1182/blood.V89.3.957
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Interferon-alpha (IFN-alpha) is an established treatment for chronic myelogenous leukemia (CML) in chronic phase, but the mechanism of its antileukemic activity is not clear. One possible mechanism of action might include the induction of apoptosis, and especially Fas-mediated cell killing may play an important role in the elimination of malignant cells. We investigated Fas receptor (Fas-R) expression and the consequences of Fas-R triggering in CML patients. Using two-color flow cytometry, we found a significantly higher number of Fas-R-expressing CD34(+) cells in the bone marrow (BM) of CML patients compared with normal subjects. We have previously shown that IFN-gamma induces Fas-R expression on CD34(+) cells; in this study, we investigated whether IFN-alpha induces Fas-R expression on CML progenitor cells. Dose-dependent induction of Fas-R expression was observed after IFN-alpha stimulation of CD34(+) cells from CML BM. In methylcellulose culture, IFN-alpha alone at a therapeutic concentration showed only marginal antiproliferative effects on both normal and CML BM progenitors. In contrast, a Fas-R agonist, the anti-CD95 monoclonal antibody CH11. inhibited colony formation from normal progenitors, and the inhibition was even stronger on CML progenitors. When CML BM cells were cultured in the presence of IFN-alpha, Fas-R-mediated inhibition of colony growth was potentiated in a dose-dependent fashion, consistent with IFN-alpha induction of Fas-R expression. This functional effect did not require the presence of accessory cells, since similar results were obtained with purified CD34(+) cells. In suspension cultures, we demonstrated that suppression of CML hematopoiesis by IFN-alpha and Fas-R agonist was exerted through Fas-R-mediated induction of apoptosis. Our findings suggest that the Fas-R/Fas-ligand system might be involved in the immunologic regulation of CML progenitor growth and that its effect can be amplified by IFN-alpha. (C) 1997 by The American Society of Hematology.
引用
收藏
页码:957 / 964
页数:8
相关论文
共 50 条
  • [21] Interferon-alpha and interferon-gamma modulate Fas-mediated apoptosis in mitomycin-C-resistant human Tenon's fibroblasts
    Wang, Xiao Yang
    Crowston, Jonathan G.
    White, Andrew J. R.
    Zoellner, Hans
    Healey, Paul R.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 (06): : 529 - 538
  • [22] Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia
    Wilhelm, M
    Bueso-Ramos, C
    O'Brien, S
    Pierce, S
    Keating, M
    Talpaz, M
    Kantarjian, HM
    LEUKEMIA, 1998, 12 (01) : 65 - 70
  • [23] Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia
    M Wilhelm
    C Bueso-Ramos
    S O’Brien
    S Pierce
    M Keating
    M Talpaz
    HM Kantarjian
    Leukemia, 1998, 12 : 65 - 70
  • [24] ACUTE-PANCREATITIS ASSOCIATED WITH INTERFERON-ALPHA THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA
    SOTOMATSU, M
    SHIMODA, M
    OGAWA, C
    MORIKAWA, A
    AMERICAN JOURNAL OF HEMATOLOGY, 1995, 48 (03) : 211 - 212
  • [25] Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia
    J Cortes
    L Fayad
    H Kantarjian
    S O’Brien
    M-S Lee
    M Talpaz
    Leukemia, 1998, 12 : 455 - 462
  • [26] RANDOMIZED COMPARISON OF INTERFERON-ALPHA WITH BUSULFAN AND HYDROXYUREA IN CHRONIC MYELOGENOUS LEUKEMIA (CML)
    HEHLMANN, R
    HEIMPEL, H
    HASFORD, J
    KOLB, HJ
    PRALLE, H
    HOSSFELD, DK
    QUEISSER, W
    LOFFLER, H
    HOCHHAUS, A
    HEINZE, B
    ANSARI, H
    BLOOD, 1994, 84 (10) : A382 - A382
  • [27] Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia
    Kattan, MW
    Inoue, Y
    Giles, FJ
    Talpaz, M
    Ozer, H
    Guilhot, F
    Zuffa, E
    Huber, SL
    Beck, JR
    ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) : 541 - +
  • [28] Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia
    Cortes, J
    Fayad, L
    Kantarjian, H
    O'Brien, S
    Lee, MS
    Talpaz, M
    LEUKEMIA, 1998, 12 (04) : 455 - 462
  • [29] INTERFERON-ALPHA THERAPY DURING PREGNANCY IN CHRONIC MYELOGENOUS LEUKEMIA AND HAIRY-CELL LEUKEMIA
    BAER, MR
    OZER, H
    FOON, KA
    BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (02) : 167 - 169
  • [30] INTERFERON-ALPHA THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA - QUESTIONS RELATED TO THE GERMAN RANDOMIZED TRIAL
    KANTARJIAN, HM
    TALPAZ, M
    BLOOD, 1995, 85 (10) : 2998 - 2999